Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.66 USD | +2.31% | -22.45% | +168.01% |
Apr. 18 | JonesTrading Starts Rezolute With Buy Rating, $10 Price Target | MT |
Mar. 06 | Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia | CI |
Business Summary
Number of employees: 57
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 66 | 10-07-25 | |
Nevan Elam
CEO | Chief Executive Officer | 56 | 10-07-25 |
Daron Evans
DFI | Director of Finance/CFO | 50 | Jan. 23 |
Chief Tech/Sci/R&D Officer | - | 21-05-19 | |
Brain Roberts
CTO | Chief Tech/Sci/R&D Officer | 49 | 16-12-31 |
Chris Milks
PRN | Corporate Officer/Principal | - | - |
Erin O’Boyle
PRN | Corporate Officer/Principal | - | 19-02-28 |
Michael Deperro
PRN | Corporate Officer/Principal | - | 15-12-31 |
Susan Stewart
LAW | General Counsel | 64 | 21-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Nevan Elam
CEO | Chief Executive Officer | 56 | 10-07-25 |
Young-Jin Kim
BRD | Director/Board Member | 67 | 19-02-09 |
Gil Labrucherie
BRD | Director/Board Member | 52 | 19-11-19 |
Philippe Fauchet
BRD | Director/Board Member | 65 | 20-09-09 |
Nerissa Kreher
BRD | Director/Board Member | 51 | 21-03-01 |
Director/Board Member | 59 | 21-03-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 40,127,647 | 31,946,451 ( 79.61 %) | 0 | 79.61 % |
Company contact information
Rezolute, Inc.
275 Shoreline Drive Suite 500
94065, Redwood City
+650 206 4507
http://www.rezolutebio.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+168.01% | 107M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RZLT Stock
- Company Rezolute, Inc.